Cancer Center Support Grant

$250,000P30FY2021CANIH

Columbia University Health Sciences, New York NY

Investigators

Linked publications, trials & patents

Paper 39764007 Paper 39763754 Paper 39730789 Paper 39694413 Paper 39678350 Paper 39677801 Paper 39677717 Paper 39672986 Paper 39632839 Paper 39605351 Paper 39525274 Paper 39510068 Paper 39484519 Paper 39475605 Paper 39427044 Paper 39424708 Paper 39416157 Paper 39391900 Paper 39389809 Paper 39386571 Paper 39383878 Paper 39383220 Paper 39374382 Paper 39372929 Paper 39345403 Paper 39334892 Paper 39315275 Paper 39265081 Paper 39257805 Paper 39257765 Paper 39256571 Paper 39229162 Paper 39229152 Paper 39196936 Paper 39195859 Paper 39192032 Paper 39183190 Paper 39180940 Paper 39179580 Paper 39178842 Paper 39164253 Paper 39141382 Paper 39134708 Paper 39105568 Paper 39105287 Paper 39095358 Paper 39094066 Paper 39030196 Paper 39024216 Paper 39009816 Paper 39007497 Paper 38991829 Paper 38956205 Paper 38935497 Paper 38933266 Paper 38902234 Paper 38854018 Paper 38848678 Paper 38848342 Paper 38838145 Paper 38831614 Paper 38824644 Paper 38824526 Paper 38809096 Paper 38798673 Paper 38776397 Paper 38769293 Paper 38767413 Paper 38754428 Paper 38741711 Paper 38739694 Paper 38717153 Paper 38684185 Paper 38657601 Paper 38645164 Paper 38625984 Paper 38621575 Paper 38609522 Paper 38588697 Paper 38588334 Paper 38585856 Paper 38559188 Paper 38555449 Paper 38522750 Paper 38522021 Paper 38521544 Paper 38511265 Paper 38483541 Paper 38454137 Paper 38450935 Paper 38428422 Paper 38402864 Paper 38385291 Trial NCT02159755 Trial NCT01627041 Trial NCT01587352 Trial NCT00233935 Patent 9387230 Patent 6756368 Patent 6218149

Abstract

PROJECT SUMMARY In this effort, we will analyze clinically-annotated tumor samples from 50 GBM patients at initial diagnosis and at time of recurrence (50 ?pairs?). We will perform single cell transcriptomic analyses at baseline and at recurrence, integrating cellular, molecular and phenotypic measurements with detailed clinical annotation, and histological and radiographic measurements to resolve the critical features that drive tumor evolution and disease progression. We will achieve this through a consortium of NCI Cancer Centers, and this will enable us to optimize statistical robustness and capture the extensive heterogeneity of the disease.

View original record on NIH RePORTER →